Cyclopamine depletes stem-like cells from glioblastoma multiforme (GBM) neurospheres and blocks tumor engraftment. (A): When GBM neurospheres were forced to differentiate, mRNA levels of the proliferation marker Ki67 and the neural stem-cell markers CD133 and Nestin decreased, along with the Hedgehog pathway targets Gli1 and Ptch1b. In contrast, markers of glial differentiation (GFAP) and neuronal differentiation (microtubule-associated protein 2) increased. (B, C): The stem-like side population was significantly decreased by cyclopamine (two-sided t test; *, p < .05; **, p < .01). (D, E): The aldehyde dehydrogenase (ALDH)-positive subpopulation of stem/progenitor cells was also depleted by cyclopamine. (F): The side- and ALDH-positive stem/progenitor cell subpopulations were depleted by cyclopamine and increased by radiation when each was given alone. Cotreatment with cyclopamine and radiation depleted side- and ALDH-positive subpopulations. (G, H): HSR-GBM1 cultures pretreated with vehicle always engrafted when either 1,000 or 10,000 viable cells counted at the end of treatment were injected into the athymic mice. In contrast, when the same number of viable cells was injected after 7 days of treatment with 10 μM cyclopamine, no detectable tumors formed (the arrow points to degenerative changes along the injection needle tract). Log-rank analysis of Kaplan-Meier survival curves indicates that the prolongation of survival associated with cyclopamine pretreatment is significant (p < .0001). Abbreviations: ALDH, aldehyde dehydrogenase; Cyc, cyclopamine; DEAB, 4-(diethylamino)benzaldehyde; GFAP, glial fibrillary acidic protein; SP, side population; SSC, side scatter; T, t test; V, vehicle; Veh, vehicle.